Rasilez and Lacrimation increased - a phase IV clinical study of FDA data

Summary:

Lacrimation increased is reported as a side effect among people who take Rasilez (aliskiren hemifumarate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Tenormin, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Lacrimation increased when taking Rasilez. It is created by eHealthMe based on reports of 5,976 people who have side effects when taking Rasilez from the FDA, and is updated regularly.

What is Rasilez?

Rasilez has active ingredients of aliskiren hemifumarate. It is often used in high blood pressure. eHealthMe is studying from 6,001 Rasilez users. Check the latest studies of Rasilez.

What is Lacrimation increased?

Lacrimation increased is found to be associated with 1,342 drugs and 1,798 conditions by eHealthMe. Check the latest studies of Lacrimation increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

5,976 people reported to have side effects when taking Rasilez.
Among them, 23 people (0.38%) have Lacrimation increased.

Could Rasilez cause Lacrimation increased?

Among these 23 people:

How long have people been on Rasilez when they have Lacrimation increased? *

What is the gender of people who have Lacrimation increased when taking Rasilez? *

female: 100 %
male: 0.0 %

What is the age of people who have Lacrimation increased when taking Rasilez? *

What are other drugs people take besides Rasilez? *

What are other side effects people have besides Lacrimation increased? *

Diarrhea: 23 people, 100.00%
Nausea And Vomiting: 21 people, 91.30%
Weakness: 16 people, 69.57%
Chest Pain: 16 people, 69.57%
Eye Pain: 15 people, 65.22%
Tension Headache: 15 people, 65.22%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 15 people, 65.22%
Indigestion: 15 people, 65.22%
Hyperkalemia (damage to or disease of the kidney): 15 people, 65.22%
Skin Discoloration: 15 people, 65.22%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 26.09%
Osteoporosis (bones weak and more likely to break): 1 person, 4.35%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.35%
Breast Cancer: 1 person, 4.35%
Back Pain: 1 person, 4.35%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 4.35%
Adrenal Disorder: 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Rasilez and have Lacrimation increased?

- Check whether Lacrimation increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rasilez:

Rasilez (6,001 reports)

Browse all side effects of Rasilez:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Lacrimation increased:

Lacrimation increased (1,342 drugs)

Browse all the conditions that are associated with Lacrimation increased:

Lacrimation increased (1,798 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aliskiren hemifumarate (the active ingredients of Rasilez) and Rasilez (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.